Editas Medicine Files 8-K Report
Ticker: EDIT · Form: 8-K · Filed: May 13, 2025 · CIK: 1650664
Sentiment: neutral
Topics: sec-filing, financials, reporting
Related Tickers: EDIT
TL;DR
EDAS filed an 8-K, mostly exhibits. Nothing major disclosed.
AI Summary
On May 13, 2025, Editas Medicine, Inc. filed an 8-K report. The filing primarily consists of financial statements and exhibits, with no specific material events or disclosures detailed in the provided text beyond the filing itself. The company is incorporated in Delaware and headquartered in Cambridge, Massachusetts.
Why It Matters
This filing indicates routine corporate reporting by Editas Medicine, Inc. to the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no new material information or significant events disclosed.
Key Numbers
- 001-37687 — SEC File Number (Identifies the company's filing with the SEC.)
- 46-4097528 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Editas Medicine, Inc. (company) — Registrant
- May 13, 2025 (date) — Date of earliest event reported
- 11 Hurley Street Cambridge, Massachusetts 02141 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION' section.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 13, 2025.
Where is Editas Medicine, Inc. headquartered?
Editas Medicine, Inc. is headquartered at 11 Hurley Street, Cambridge, Massachusetts 02141.
What is the SEC file number for Editas Medicine, Inc.?
The SEC file number for Editas Medicine, Inc. is 001-37687.
What industry is Editas Medicine, Inc. classified under?
Editas Medicine, Inc. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with the SIC code [2836].
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 13, 2025 regarding Editas Medicine, Inc. (EDIT).